The existence of relationship between cancer and metal is known to all oncologists. However, various aspects about these relationships are ignored by many. It is surprising to observe that metals are able to do the best and the worst. i.e. metals are able to induce cancer and to treat cancer. Some of them are even able to perform both, together with them organic derivative have been tested for their anti-proliferative activity. The toxicity as well as therapeutic value of organo metallic compounds of these elements is a continuing 
Introduction
signaling path ways responsible for cell growth and apoptosis. Arsenic induces chromosomal abnormalities and disruption of DNA methylation and of repair systems. Arsenic induced oxidative stress with subsequent DNA damage could explain the toxicity of arsenic. The actions of arsenic can eliminate transformed cells, which could protect organism from cancer and possibly could be its mechanism as arsenic and vanadium. Almost all metals are able to generate reactive Oxygen species (ROS), this property explains a great part of both their carcinogenicity and their aptitude to neat cancer. Oxygen is an absolute necessity for life and it is also worst carcinogenic molecule that we must endure during all over life time. This means that we must be careful to always manage a good reserve of intracellular reducing potential. Among the non platinum group metals, non transition metal and metalized, viz, Ga, Sn, As, Sb and bismuth along with selenium of action against tumour cells.
Tin:
Because platinum and tin have common properties, for instance their possible oxidation states, tin compounds were screened as early as in 1980. The first organotin compounds, for which the antitumour properties were examined, were formally similar to cisplatin, or to its analogous carboplatin or paraplatin. They exhibit borderline activities against P-388 and L210 leukaemias in vivo. Arakawa studied the in vivo activity of di-nbutyltin dichloride towards Ehrlich ascities tumour, IMC carcinoma, P-388 lymphocytic leukemia and sarcoma 180 systems, and also showed that this compound influences of the DNA synthesis of proliferating cells. Many diorganotin compounds, R 2 SnX 2 , were investigated in the content of their antitumour potential. The influence of the R groups and of the X ligands on the cavity was examined. (Gielen, 2002 Among the observed toxicities, neurotoxicity, known from platinum cytostatics and gastrointestinal toxicity typical for many oncology drugs, have been detected, but to lower extent. Further research to develop novel useful organotin antitumour compounds needs to be carried out (Gielen, et al. 1992 , Gielen 1994 .
Gallium:
Gallium is the second metal ion, after platinum, to be used in cancer treatment (Collery et al., 2002) . Its activities are numerous and various. It modifies three dimensional structure of DNA and inhibits synthesis, modulates protein synthesis, inhibits the activity of a number of enzymes such as ATPase, DNA polymerases, ribonucleotide reductase and tyrosine-specific protein phosphatase. Ga alters plasma membrane permeability and mitochondrial functions. Ga salts are taken up more efficiently and more specifically by tumor cells when orally administered. New compounds have been prepared. Gamaltolate, doxorubicin-Ga-transferring conjugate and Tris (8-quinolinoloto) Ga (III), which show interesting activities. Ga toxicity is well documented in vitro and in vivo in animals. In humans, the oral administration Ga is less toxic and allows a chronic treatment, allowing an improvement of its bioavailability in tumours by comparison with the parenteral use. The anticancer activity of Ga salts has been demonstrated but other effects have also been noted such as many bone effects that could be useful in bone metastatic patients. It has also been shown that a long period of administration could induce tumour fibrosis Ga is synergistic with other anti cancer activity of Ga should not be ignored, but the schedule of administration still needs to be optimized and new compounds are now under clinical investigation. (Collery et al., 1991) .
Bismuth:
In the medical field, bismuth compounds are used to relive diaper (nappy) rash, treat burns as well as to treat gastric disorders such as diarrhea. Importantly, bismuth compounds are effective against the bacterium; helicobacter pylori (abbreviated H.pylori) which causes peptic ulcers. Peptic ulcers are sores which are formed in the stomach wall or duodenum of the small intestine. Previously, it was thoughs that peptic ulcers were caused by eating spicy food or by stress.
However, in 1982, it was discovered that the bacterium, H.pylori, is responsible for peptic ulcers. H.pylori is a rod shaped, spiral bacterium. It weakens the protective mucous lining of the stomach and duodenum and thus allows the stomach acid to irritate the sensitive stomach wall. It is suspected that stomach cancer may also develop from the presence of H-pylori. Hence it is important to try and eradicate the bacteria. At present bismuth subcitrate and bismuth subsalicilate are used to treat such medical conditions, of which both are Bi (III) ions. Their empirical formulas are often given as K 3 (NH 4 1983 & Haiduc, et al. 1995 .
The potential of bismuth as anti-cancer drugs has not been fully explored despite the use of bismuth in other medical applications. As some other organometallic compounds have been shown to be biologically active against human cancer cell lines, the possibility of bismuth compounds as anti-tumour drugs has been investigating. Studies of bismuth 6-mercaptopyrine and other thiolates have already shown some anti-tumor activity. Bi(SR) 3 has been shown to be more potent than platinum(II) analogue [Pt(SR) 2 ] and at higher doses than the palladium (II) species.
Antimony: Despite their medicinal efficacy, the exploration of the antitumour potential of an1timony compounds is not as well developed as for other metal containing species. The results of cytotoxicity and antitumour screening for antimony and antimony (V) compounds have been reviewed (Tiekink, 2002) . The most studied antimony (III) compounds in the context of antitumour activity are organometallic in that they feature antimony to carbon bonds. Thus, a pair of diphenyl antimony (III) thiolates, i.e., Ph 2 Sb(S 2 PPh 2 ) and Ph 2 Sb(S 2 POPr) 2 have been investigated. Early work on these and related compounds both in vitro and in vivo, showed that compounds containing antimony (III) were more active than their organotin congeners and that Ph 2 SbS 2 P(OPr) 2 was more active than Ph 2 Sb (S 2 PPh 2 ) against Ehrlich ascites tumour. The in vivo screening against P-388 leukaemia in mice has been investigated. Three of the four antimony (III) compounds were found to have marginal activity (Tic<125%) and definitely not as active as the widely employed anti-cancer drug cis-platin, i.e., (NH 3 ) 2 PtCl 2 , in this model. Compound Ph 2 SbS 2 P(OPr) 2 was the most active but increased doses were associated with increased toxicity. A Subsequent studies showed that both Ph 2 Sb(S 2 PPh 2 ) and Ph 2 SbS 2 P(OPr) 2 and mutagenic potential with Ph 2 SbS 2 P(OPr) 2 having the higher effect. (Tiekink, 2002) . Sodium stibogluconate (SSG) appears to be a better inhibitor than suramin which is compound known for its antineoplastic activity against several types of cancer (Cabrera, et al., 2008) .
Two reports are available on the cytoxicity of antimony (V) compounds (Carraher et al., 1983 , Haiduc, 1995 . In the first report the potential inhibitory effects of series triphenyl antimony (V) polyamines were described. The results of this study show that all compounds displayed some inhibition and the assay showed that, generally, increased inhibition was associated with increased doses. The most potent compounds across the series of three cell lines (BHK-21 baby hamster kidney, L929 mouse connective tissue and HeLa human epitheloid carcinoma) were those containing the dianions derived from adenine (H 2 NR 2 ) and 2,6-diaminoanthraquinone (H 2 HR 7 ). Selectivity against the BHK-21 cell line compared with the other cell lines was exhibited by the compound containing the dianion derived from 2,4-diamino-S(3,4-dimethoxybenzil) pyrimidine (H 2 NR 6 ).
The second report of antimony(V) compounds studied for cytotoxicity described monomeric species of the general formula R 3 Sb(O 2 CC 6 H 3 -2-OH-S-Y) 2 where R=Me or Ph and Y=H Me or OMe. Screening against a variety of human tumour cell lines showed that these species had no significant activity and their study was not pursued (Haiduc, et al., 1995) .
Experimental
In-vitro Antitumour Testing: The cell proliferation activity of the compounds was measured by using MTT method. Measurement of cell viability and proliferation forms the basis for mumerous in vitro assays of all populations' response to external factors. The reduction of tetrazoleum salts is now widely accepted as a reliable ways to examine the cell proliferation activity.
The yellow coloured tetrazoleum MTT (3-(4,5) dimethyeltetrazoyl-2)-2,5-diphenyl tetrazoleum bromide) is reduced by metabolically active cell line; by the action of dehydrogenase enzymes; to generate reducing equivalent such as NADH and NADPH. The resulting purple color can be solubilised and quantified by spectrophotometer method.
Results and Discussion
The antitumour screening result of Ar 3 SbL 2 (Ar=C 6 F 5 , C 6 H 5, p-CH 3 C 6 H 4 :L=NR 2 , OCOR) are presented in Table 1 . desirable for better antitumour activity of antimony (v) derivatives.
